ATE409495T1 - Polynukleotide-bindende komplexe die sterolen und saponine enthalten - Google Patents

Polynukleotide-bindende komplexe die sterolen und saponine enthalten

Info

Publication number
ATE409495T1
ATE409495T1 AT02759762T AT02759762T ATE409495T1 AT E409495 T1 ATE409495 T1 AT E409495T1 AT 02759762 T AT02759762 T AT 02759762T AT 02759762 T AT02759762 T AT 02759762T AT E409495 T1 ATE409495 T1 AT E409495T1
Authority
AT
Austria
Prior art keywords
complexes
saponins
methods
determinant
polynucleotide binding
Prior art date
Application number
AT02759762T
Other languages
English (en)
Inventor
Nikolai Kirkby
Kristian Dalsgaard
Original Assignee
Nordic Vaccine Technology As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nordic Vaccine Technology As filed Critical Nordic Vaccine Technology As
Application granted granted Critical
Publication of ATE409495T1 publication Critical patent/ATE409495T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Mycology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cosmetics (AREA)
AT02759762T 2001-04-04 2002-04-04 Polynukleotide-bindende komplexe die sterolen und saponine enthalten ATE409495T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA200100560 2001-04-04
US30860901P 2001-07-31 2001-07-31

Publications (1)

Publication Number Publication Date
ATE409495T1 true ATE409495T1 (de) 2008-10-15

Family

ID=26069002

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02759762T ATE409495T1 (de) 2001-04-04 2002-04-04 Polynukleotide-bindende komplexe die sterolen und saponine enthalten

Country Status (7)

Country Link
EP (2) EP2011517A1 (de)
JP (2) JP2004528321A (de)
AT (1) ATE409495T1 (de)
DE (1) DE60229118D1 (de)
DK (1) DK1377320T3 (de)
NZ (1) NZ529347A (de)
WO (1) WO2002080981A2 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006503072A (ja) * 2002-10-02 2006-01-26 ノルディック ワクチン テクノロジー アクティーゼルスカブ ワクチン接種用組成物
WO2009106085A1 (en) * 2008-02-28 2009-09-03 Nordic Vaccine A/S Vaccine compositions comprising saccharide antigens
AU2012319239B2 (en) 2011-10-03 2017-04-20 Mx Adjuvac Ab Nanoparticles, process for preparation and use thereof as carrier for amphipatic of hydrophobic molecules in fields of medicine including cancer treatment and food related compounds
US9907846B2 (en) 2013-04-01 2018-03-06 Mx Adjuvac Ab Nanoparticles, composed of sterol and saponin from Quillaja saponaria Molina for use in pharmaceutical compositions
EP3652190B1 (de) 2017-07-11 2023-06-14 Freie Universität Berlin Neuartige verwendungen eines saponins und verfahren zu dessen isolierung
CN108498376B (zh) * 2018-04-02 2020-11-13 榛硕（武汉）智能科技有限公司 一种甲基硅油乳液及其制备方法
CN109295080B (zh) * 2018-09-19 2021-08-20 昆明理工大学 珠子参β-香树脂醇合成酶基因Pjβ-AS的用途

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4162282A (en) 1976-04-22 1979-07-24 Coulter Electronics, Inc. Method for producing uniform particles
GB2064320B (en) 1979-10-13 1983-10-12 Welsh Nat School Med Intra-ocular irrigation fluid
US4310505A (en) 1979-11-08 1982-01-12 California Institute Of Technology Lipid vesicles bearing carbohydrate surfaces as lymphatic directed vehicles for therapeutic and diagnostic substances
US4533254A (en) 1981-04-17 1985-08-06 Biotechnology Development Corporation Apparatus for forming emulsions
US4443432A (en) 1981-10-05 1984-04-17 Alcon Laboratories, Inc. Ophthmalic irrigating solution
US4550022A (en) 1981-10-05 1985-10-29 Alcon Laboratories, Inc. Tissue irrigating solution
US4526714A (en) 1982-12-13 1985-07-02 Cordis Europa N.V. Conjugates of anticoagulant and protein
SE8205892D0 (sv) 1982-10-18 1982-10-18 Bror Morein Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin
SE450674B (sv) 1982-11-17 1987-07-13 Volvo Ab Kabelholje
US4728575A (en) 1984-04-27 1988-03-01 Vestar, Inc. Contrast agents for NMR imaging
CA1264668A (en) 1984-06-20 1990-01-23 Pieter R. Cullis Extrusion techniques for producing liposomes
US4921706A (en) 1984-11-20 1990-05-01 Massachusetts Institute Of Technology Unilamellar lipid vesicles and method for their formation
NZ217844A (en) 1985-10-11 1989-10-27 Sumitomo Pharma A sustained release pharmaceutical composition containing silicone elastomer and an albumin
US4737323A (en) 1986-02-13 1988-04-12 Liposome Technology, Inc. Liposome extrusion method
IL79559A0 (en) 1986-07-29 1986-10-31 Univ Ramot Contrast agents for nmr medical imaging
US4728578A (en) 1986-08-13 1988-03-01 The Lubrizol Corporation Compositions containing basic metal salts and/or non-Newtonian colloidal disperse systems and vinyl aromatic containing polymers
US5554372A (en) 1986-09-22 1996-09-10 Emory University Methods and vaccines comprising surface-active copolymers
US4938970A (en) 1987-02-06 1990-07-03 Hustead Robert E Painless electrolyte solutions
US5583112A (en) 1987-05-29 1996-12-10 Cambridge Biotech Corporation Saponin-antigen conjugates and the use thereof
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
NZ230747A (en) 1988-09-30 1992-05-26 Bror Morein Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina
EP0442962B1 (de) 1988-11-09 1994-01-05 UNGER, Evan C Liposomale radiologische kontrastmittel
FR2645866B1 (fr) 1989-04-17 1991-07-05 Centre Nat Rech Scient Nouvelles lipopolyamines, leur preparation et leur emploi
AU651319B2 (en) 1989-07-27 1994-07-21 Univax Biologics Incorporated Lipid A analog/immunogenic carrier conjugates and the use thereof as vaccines
NL9002314A (nl) 1990-10-23 1992-05-18 Nederlanden Staat Immunogene complexen, in het bijzonder iscoms.
GB9106673D0 (en) 1991-03-28 1991-05-15 Hafslund Nycomed As Improvements in or relating to contrast agents
JPH06507904A (ja) 1991-05-23 1994-09-08 イマアーレクス・フアーマシユーチカル・コーポレーシヨン 磁気共鳴画像形成用の油脂可溶化合物
SE502569C2 (sv) * 1991-05-31 1995-11-13 British Tech Group Användning av en immunologiskt inert matris av en sterol och saponiner som kan bilda sfäriska nanopartiklar med snäv storleksfördelning som läkemedelsbärare, partiklar, komposition samt kit
US5273965A (en) 1992-07-02 1993-12-28 Cambridge Biotech Corporation Methods for enhancing drug delivery with modified saponins
US5650398A (en) 1992-07-02 1997-07-22 Cambridge Biotech Corporation Drug delivery enhancement via modified saponins
WO1995009179A1 (en) 1993-09-30 1995-04-06 Seed Capital Investments (Sci) B.V. Compounds with adjuvant activity
AU2112697A (en) * 1996-02-09 1997-08-28 Pi-Wan Cheng Receptor ligand-facilitated delivery of biologically active molecules
CA2260761C (en) 1996-06-25 2011-05-03 Nico Johannes Christiaan Maria Beekman Vaccine comprising antigens bound to carriers through labile bonds
JP3963506B2 (ja) * 1996-08-26 2007-08-22 俊彦 松尾 リポソーム点眼剤
AUPO517897A0 (en) * 1997-02-19 1997-04-11 Csl Limited Chelating immunostimulating complexes
US6120751A (en) 1997-03-21 2000-09-19 Imarx Pharmaceutical Corp. Charged lipids and uses for the same
EP0979100A1 (de) * 1997-04-30 2000-02-16 Merieux OraVax SNC Anti-helicobacter impfstoffzusammensetzung die ein th1 - typ adjuvans enthält
US6080725A (en) 1997-05-20 2000-06-27 Galenica Pharmaceuticals, Inc. Immunostimulating and vaccine compositions employing saponin analog adjuvants and uses thereof
AUPO732997A0 (en) * 1997-06-12 1997-07-03 Csl Limited Ganglioside immunostimulating complexes and uses thereof
DE19740092A1 (de) * 1997-09-12 1999-03-18 Ulrich Dr Med Hengge Liposomen und Verfahren zur Transfektion von Zellen
US6013258A (en) * 1997-10-09 2000-01-11 Zycos Inc. Immunogenic peptides from the HPV E7 protein
US7491409B1 (en) * 1999-03-02 2009-02-17 Transave, Inc. Encapsulation of bioactive complexes in liposomes
EP1292330A1 (de) 2000-03-31 2003-03-19 Vaccine Chip Technology APS Immunostimulierende eigenschaften eines tgf-beta-fragmentes

Also Published As

Publication number Publication date
DE60229118D1 (de) 2008-11-13
EP2011517A1 (de) 2009-01-07
DK1377320T3 (da) 2009-02-09
JP2004528321A (ja) 2004-09-16
WO2002080981A2 (en) 2002-10-17
EP1377320A2 (de) 2004-01-07
NZ529347A (en) 2008-01-31
EP1377320B1 (de) 2008-10-01
JP2010180249A (ja) 2010-08-19
WO2002080981A3 (en) 2002-12-19

Similar Documents

Publication Publication Date Title
EP2301531A3 (de) Kombinationen und modi zur verabreichung therapeutischer mittel und kombinationstherapie
EP2322215A3 (de) Kombinationsbehandlung für nicht-hämatologische bösartige Erkrankungen mit einem anti-IGF-1R-Antikörper
MXPA05006940A (es) Formulaciones terapeuticas para el tratamiento de enfermedades relacionadas con beta - amiloide.
ATE355065T1 (de) Therapeutische zusammensetzungen bestehend aus antihypotensiva und antiangiogenika
HUP0300421A2 (hu) Kezelési eljárás ligand-immunogén konjugátumok felhasználásával
RU95109905A (ru) Композиции в жидком, полутвердом, твердом, гелеобразном или пастообразном виде и способ лечения заболеваний полости рта
WO2007049098A3 (en) Therapeutic formulations for the treatment of beta-amyloid related diseases
HU0102039D0 (en) Use of paclitaxel stabilized with albumin for the preparation of pharmaceutical compositions treating solid tumors and the pharmaceutical compositions obtained thereby
CA2301057A1 (en) A method of administering liposomal encapsulated taxane
WO2004060384A3 (en) Pharmaceutical botulinum toxin compositions
WO2005051429A3 (en) Targeted conjugates with a modified saccharide linker
WO2005025508A3 (en) Magnetically targetable particles comprising magnetic components and biocompatible polymers for site-specific delivery of biologically active agents
WO2001038303A3 (fr) Analogues de la vitamine d
IL173481A0 (en) Polysaccharide double-layer microcapsules as carriers for biologically active substance oral administration
ATE409495T1 (de) Polynukleotide-bindende komplexe die sterolen und saponine enthalten
WO2002102311A3 (en) Nanoparticles for treating targeted tissues and cells
BR0015149A (pt) Método e composições para administração de taxanos oralmente a pacientes humanos
WO1999018998A3 (en) Delivery system
Chase et al. Curaderm, the long-awaited breakthrough for basal cell carcinoma
BR0116653A (pt) Medicamento contendo uma poliamina como substância ativa
BR9912533A (pt) Composição farmacêutica tendo sabor melhorado
DE60129606D1 (de) Mittel und verfahren zur vorbeugung von durch chemotherapie ausgelöster alopezie
DE69326627T2 (de) Therapeutisches Mittel gegen drohenden Abortus
WO2001080891A8 (fr) Substances medicamenteuses destinees a la pneumonie interstitielle, procede de construction d'un modele animal de cette maladie et procede de criblage dans lequel on utilise ce dernier
ATE331523T1 (de) Statin-therapie zur verbesserung der aufrechterhaltung der kognitiven funktion

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties